We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck Withdraws Application for Keytruda for Third-Line Gastric Cancer Treatment
Merck Withdraws Application for Keytruda for Third-Line Gastric Cancer Treatment
Merck is withdrawing its accelerated approval application to the FDA for its blockbuster cancer drug Keytruda (pembrolizumab) for third-line treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, following disappointing study results.